FDA Updates Hologic BioZorb Recall, Citing 252 Injuries

The Food and Drug Administration (FDA) has reported 252 injuries associated with Hologic's BioZorb radiographic markers, which are implanted in breast and other soft tissue during medical procedures. This update comes nearly two years after Hologic advised customers to cease using the devices due to adverse events such as pain, infection, and device migration. No deaths have been reported. While the company no longer manufactures the markers, healthcare providers are still advised not to use them and to monitor patients with implanted devices for adverse events.

Context

Hologic's BioZorb markers were designed to assist in radiographic imaging but have been linked to various adverse events since their use. The FDA's warning comes after Hologic advised against using the markers nearly two years ago due to reports of pain, infection, and device migration. The company has ceased manufacturing the markers, yet the devices remain in some patients.

Why it matters

The FDA's update on the Hologic BioZorb recall highlights ongoing safety concerns regarding medical devices used in breast and soft tissue procedures. The reported injuries underscore the potential risks associated with these implants, affecting patient health and trust in medical technology. Monitoring patients with these devices remains crucial to prevent further complications.

Implications

Patients with BioZorb implants may experience ongoing health issues, leading to potential medical interventions. Healthcare providers may face increased scrutiny and liability related to the use of these devices. The situation may prompt regulatory bodies to reevaluate the approval processes for similar medical devices in the future.

What to watch

Healthcare providers will need to continue monitoring patients who have received BioZorb implants for any adverse effects. The FDA may issue further guidance or recommendations as more data on injuries becomes available. The response from healthcare professionals and patients regarding the recall will be important to observe.